TickerFacts.

Compare

Kymera Therapeutics, Inc. vs Sangamo Therapeutics, Inc vs C4 Therapeutics, Inc. vs X4 Pharmaceuticals, Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearKymera Therapeutics, Inc.
KYMR		Sangamo Therapeutics, Inc
SGMOQ		C4 Therapeutics, Inc.
CCCC		X4 Pharmaceuticals, Inc
XFOR
Year ended2025-12-312025-12-312025-12-312025-12-31
Revenue$39.21M$39.55M$35.95M$35.11M
Revenue growth (YoY)-16.7%-31.6%+1.0%n/m
Gross margin0.0% (computed)n/an/a83.6% (computed)
Operating margin-891.1%-306.5%-320.5%-247.4%
Net margin-794.0%-310.8%-292.1%-225.6%
Net income-$311.35M-$122.93M-$104.99M-$79.20M
EPS (Diluted)-$3.69-$0.44-$1.27-$1.87
Operating cash flow-$232.89M-$97.21M-$98.69M-$85.62M
Free cash flow-$234.34M-$97.31M-$99.30M-$85.62M
Cash & equivalents$357.01M$20.95M$74.60M$217.05M
Total assets$1.74B$59.74M$359.07M$290.46M
Total liabilities$163.15M$74.01M$102.49M$104.17M
Shareholders' equity$1.58B-$14.27M$256.59M$186.29M
Return on year-end equity-19.7%n/a-40.9%-42.5%
Shares outstanding81.32M350.69M96.91M90.91M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearKymera Therapeutics, Inc.Sangamo Therapeutics, IncC4 Therapeutics, Inc.X4 Pharmaceuticals, Inc
Latest$39.21M
Ended 2025-12-31		$39.55M
Ended 2025-12-31		$35.95M
Ended 2025-12-31		$35.11M
Ended 2025-12-31
1 year earlier$47.07M
Ended 2024-12-31		$57.80M
Ended 2024-12-31		$35.58M
Ended 2024-12-31		$2.56M
Ended 2024-12-31
2 years earlier$78.59M
Ended 2023-12-31		$176.23M
Ended 2023-12-31		$20.76M
Ended 2023-12-31		$0
Ended 2023-12-31
3 years earlier$46.83M
Ended 2022-12-31		$111.30M
Ended 2022-12-31		$31.10M
Ended 2022-12-31		$0
Ended 2022-12-31
4 years earlier$72.83M
Ended 2021-12-31		$110.70M
Ended 2021-12-31		$45.78M
Ended 2021-12-31		$0
Ended 2021-12-31